Achilles Tendon Thickening as a Cardiovascular Risk Marker

Most people who think about cardiovascular risk think about cholesterol panels, blood pressure, or maybe a calcium scan.

Almost no one thinks about their Achilles tendon.

They should. A 2023 study of 1,362 patients who had undergone percutaneous coronary intervention (PCI) found that patients with thickened Achilles tendons had 99% higher risk of major adverse cardiovascular events (MACE) compared to those with normal tendon thickness. Double the risk, from a $50 ultrasound or a simple clinical measurement.

This is one of the most underreported cardiovascular findings of the past five years. It isn’t on the checklist at your annual physical. But the mechanism behind it connects directly to something every longevity-focused person should understand: the concept of lifetime LDL burden.

Why Your Achilles Tendon Reflects Your Cardiovascular History

The connection between Achilles tendons and cardiovascular disease was first established in research on familial hypercholesterolemia (FH) — a genetic condition that causes extremely high LDL from birth.

People with FH develop cholesterol deposits in unusual places: around the eyes (xanthelasmas), in tendons (xanthomas), and in arteries. The Achilles tendon, the thickest tendon in the body, is particularly susceptible to xanthoma deposition — cholesterol-laden macrophages accumulating in the tendon tissue over years of exposure to elevated LDL.

Tsouli et al. (2005) published a comprehensive review of tendon xanthomas in FH, documenting the pathogenesis and their role as markers of LDL burden (PMID: 15816992). The more recent finding is that tendon thickening isn’t limited to people with diagnosed FH — it also occurs in people with chronically elevated LDL who don’t have the genetic diagnosis. The 2023 PCI study extended this: in a real-world cohort of cardiac patients, measurable Achilles tendon thickening predicted twice the risk of future cardiovascular events, independent of traditional risk factors.

The mechanism is the same whether or not you have FH: years of elevated ApoB-containing particles circulating in the bloodstream leads to lipid deposition not only in arterial walls but in high-stress connective tissues. The Achilles tendon, which bears loads of 6-8x body weight during running, is one of the most common sites.

The Lifetime LDL Burden Concept

The traditional approach to cardiovascular risk focuses on current LDL levels. Your most recent lipid panel shows 130 mg/dL, and a risk calculator gives you a 10-year event probability. The problem with this approach is that cardiovascular disease is primarily a disease of cumulative exposure, not point-in-time measurement.

Sniderman et al. (2019, JAMA Cardiology, PMID: 31642874) laid out the ApoB argument precisely: ApoB is a better predictor of cardiovascular events than LDL-C because it counts the particles directly rather than estimating their cholesterol content. Each ApoB-containing particle can embed in an arterial wall. The total number of embedding events over a lifetime determines plaque burden.

A useful way to think about this is “mmol·years” — the product of LDL level and years of exposure. Consider two people: Person A with LDL of 2.0 mmol/L from age 20 to 70 = 100 mmol·years exposure. Person B with LDL of 4.0 mmol/L from age 20 to 70 = 200 mmol·years exposure. Person B has twice the cumulative exposure, even if their most recent LDL test looks “moderately elevated” rather than severely high.

The Achilles tendon reflects this cumulative history in a way that a single blood test cannot. It’s not a snapshot of today’s risk — it’s a record of decades of lipid exposure written in connective tissue.

How to Measure Achilles Tendon Thickness

Ultrasound (preferred): Musculoskeletal ultrasound is the gold standard. Non-invasive, radiation-free, takes about 10 minutes. Normal Achilles tendon thickness by ultrasound is typically defined as under 6mm. Values above 8-9mm are generally considered abnormal. Cost in the US: typically $100-250 for a bilateral Achilles ultrasound.

X-ray: Can detect the soft tissue shadow of the Achilles tendon and identify gross thickening and calcifications. Less precise than ultrasound for subtle changes. More widely available and less expensive.

Self-palpation: Pinch the tendon about 2-3cm above the heel with thumb and forefinger. A very thick tendon feels almost like a rope. Obvious asymmetry between the two sides is worth noting. This isn’t a clinical measurement, but it’s a reasonable reason to ask for an ultrasound.

Tendon Xanthomas vs. Plain Thickening: What’s the Difference

Tendon xanthomas are lipid deposits — collections of cholesterol-laden macrophages within the tendon tissue. They look and feel like firm nodules. Tendon xanthomas are pathognomonic for FH in the right clinical context: if a person under 50 has Achilles tendon xanthomas plus elevated LDL, FH should be suspected and genetic testing offered.

Plain tendon thickening without xanthomas is more diffuse — the tendon is uniformly enlarged but without discrete nodules. This is what’s been associated with elevated cardiovascular risk in the broader (non-FH) population. The 2023 PCI study finding applied to this type of thickening, not just to classical xanthomas.

Achilles tendinopathy can also cause tendon thickening through a different mechanism: collagen disruption and scar tissue formation from mechanical overload. This type of thickening is associated with pain and exercise history, and doesn’t carry the same cardiovascular significance. A clinician can usually distinguish the two based on clinical context and ultrasound appearance.

The ApoB Connection

If Achilles tendon thickness reflects cumulative LDL exposure, then ApoB is the number that most directly explains the risk. Each LDL particle carries one ApoB molecule. Measuring ApoB counts the particles; measuring LDL-C estimates their cholesterol content. LDL-C can appear normal even when particle count is elevated — ApoB catches these cases.

The practical implication: if your Achilles tendons appear thickened and your LDL looks borderline, check ApoB. A finding of elevated ApoB (over 1.0 g/L for general risk, over 0.9 g/L for high-risk patients) alongside Achilles tendon thickening represents a meaningful dual signal.

Reversibility: What Happens After Treatment

Can Achilles tendon thickness reverse with lipid-lowering treatment? The evidence is limited but cautiously optimistic. Case reports and small series in FH patients treated with high-intensity statins or PCSK9 inhibitors have shown partial tendon xanthoma regression over years of treatment. Full regression is uncommon; partial reduction in thickness appears possible, particularly in younger patients with shorter duration of lipid deposition.

PCSK9 inhibitors, which reduce LDL-C by 50-60% on top of statin therapy, show more promising tendon regression data than statins alone. In non-FH patients, there’s essentially no prospective data on tendon thickness regression — but the inference from FH data is that aggressive, early lipid lowering reduces cumulative exposure and may slow or partially reverse deposition.

What to Do With This Information

Who should consider Achilles tendon ultrasound: Anyone with a family history of premature cardiovascular disease. Anyone with persistently elevated LDL above 160 mg/dL or ApoB above 1.0 g/L. Anyone with a personal history of cardiovascular disease or a coronary calcium score above zero. Anyone who notices asymmetric tendon thickening or firm nodules in the Achilles.

What to do if the ultrasound shows thickening: It’s additional risk information to bring to your physician, not a diagnosis. A finding of Achilles tendon thickening should prompt: full lipid panel with ApoB, consideration of a coronary calcium score (CAC), and a discussion of whether lipid-lowering therapy is warranted at a lower threshold than standard guidelines suggest.

The Mandsager et al. (2018) study in JAMA Network Open (PMID: 30646252), which tracked 122,000 people for 23 years, found that low cardiorespiratory fitness (VO2max) was the strongest predictor of all-cause mortality — stronger than coronary artery disease, diabetes, or smoking. Achilles tendon thickening identifies historical lipid burden; VO2max identifies current physiological reserve. Using both together gives a more complete picture of where you actually stand.

FAQ

How thick should a normal Achilles tendon be?

Normal Achilles tendon thickness measured by ultrasound is generally under 6mm. Values of 6-8mm are borderline depending on the study, and values above 8-9mm are typically considered abnormal. The threshold also depends on body size and the specific measurement protocol. A sports medicine physician or radiologist can provide context for your specific measurement.

Can you feel a thickened Achilles tendon yourself?

Sometimes. Gross thickening or tendon xanthomas may be palpable as firm, irregular areas within the tendon substance. Pinching the tendon 2-3cm above the heel between thumb and forefinger and comparing both sides is a reasonable self-check. Nodules, asymmetry, or unusual firmness are worth mentioning to a doctor — not because they necessarily indicate cardiovascular disease, but because they warrant proper evaluation.

Does Achilles tendon thickness change with exercise?

Yes, but through a different mechanism than lipid deposition. Regular loading of the Achilles (running, jumping) causes adaptive hypertrophy — the tendon gets slightly thicker and stronger in response to mechanical stress. This is a healthy adaptation and looks different on ultrasound from pathological thickening. Adaptive thickening tends to be uniform, bilateral, and associated with organized collagen structure. Lipid-related thickening tends to be heterogeneous with altered tissue echogenicity.

Is ultrasound or X-ray better for measuring tendon thickness?

Ultrasound is better. It’s the gold standard for soft tissue evaluation — non-invasive, no radiation, and provides precise quantitative measurements. X-ray can detect gross thickening and calcifications but is less sensitive for subtle changes. In clinical research, ultrasound is the standard method.

Can statins reduce Achilles tendon thickness?

Modestly, in some cases. Case series in familial hypercholesterolemia patients show partial tendon xanthoma regression with high-intensity statins over years of treatment. PCSK9 inhibitors, which reduce LDL more dramatically, show better regression data. In non-FH patients with plain thickening, there’s no prospective trial data — but the inference from FH research is that aggressive lipid lowering slows progression and may allow partial regression.

What other tendons can show cholesterol deposits?

The extensor tendons of the hands (particularly over the knuckles) and the patellar tendon are the next most common sites. Xanthelasmas (deposits around the eyes) are a related finding. In severe FH, tuberous xanthomas can appear at pressure points like elbows and knees. The Achilles is the most common site studied because it’s most reliably correlated with cardiovascular risk.

Is Achilles tendinitis the same as tendon thickening?

No. Achilles tendinopathy is a degenerative condition caused by mechanical overload or age-related collagen changes. It causes pain, stiffness, and structural disruption of the tendon. It can cause thickening, but through a completely different mechanism than lipid deposition. The two can coexist, but clinical presentation and ultrasound appearance help distinguish them. Tendinopathy doesn’t carry the cardiovascular significance of lipid-related thickening.

At what age should you start checking your Achilles tendon?

If you have familial hypercholesterolemia or strong family history of premature cardiovascular disease, screening is reasonable from early adulthood. For the general population, adding Achilles tendon ultrasound to a cardiovascular health assessment makes most sense starting around age 40-50, particularly if ApoB or LDL is elevated. Earlier if you have coronary calcium detected or a significant family history.

References

1. Tsouli SG, et al. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest. 2005;35(4):236-244. PMID: 15816992. pubmed.ncbi.nlm.nih.gov/15816992
2. Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. PMID: 31642874. pubmed.ncbi.nlm.nih.gov/31642874
3. Mandsager K, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605. PMID: 30646252. pubmed.ncbi.nlm.nih.gov/30646252
4. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl (REDUCE-IT). N Engl J Med. 2019;380:11-22. PMID: 30415628. pubmed.ncbi.nlm.nih.gov/30415628

Last reviewed by MVHK — May 2026.